Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michelle Van Nieuwenhize

Internal Medicine Lincoln, RI Medical Doctor

NPI 1386653343 CMS profile 334664

6 Blackstone Valley Pl, Building #3 Suite 305, Lincoln, RI 02865

Open in the dashboard

General payments

$1,310

49 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michelle Van Nieuwenhize of Lincoln, RI is reported in the CMS Open Payments database as having received $1,310 across 49 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 74th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $261 6
2024 General $221 11
2023 General $284 12
2022 General $198 5
2021 General $44 2
2020 General $31 2
2019 General $272 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michelle Van Nieuwenhize
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Michelle Van Nieuwenhize were reported at $261. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Michelle Van Nieuwenhize Internal Medicine median Middle half National median
2019 $272 $159 $48–$570 $163
2020 $31 $119 $33–$402 $114
2021 $44 $135 $37–$521 $132
2022 $198 $141 $42–$496 $149
2023 $284 $149 $45–$519 $160
2024 $221 $154 $47–$537 $164
2025 $261 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Merz North America, Inc. $476 20 payments
  2. AbbVie, Inc. $279 7 payments
  3. Pfizer Inc. $224 12 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $128 2 payments
  5. Allergan Inc. $122 4 payments
  6. Biohaven Pharmaceutical Holding Company Ltd. $27 1 payment
  7. Novartis Pharmaceuticals Corporation $24 1 payment
  8. Agios Pharmaceuticals, Inc. $17 1 payment
  9. Salix Pharmaceuticals, a division of Bausch Health US, LLC $14 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,294 48 payments
  2. Education $17 1 payment
Products named General payments · program years 2019–2025
  1. Xeomin $327 15 payments
  2. NURTEC ODT Pain $207 10 payments
  3. BOTOX $143 1 payment
  4. ASCLERA $128 6 payments
  5. GLASSIA $128 2 payments
  6. ZAVZPRET $127 6 payments
  7. BOTOX COSMETIC $122 4 payments
  8. PAXLOVID $107 6 payments
  9. COMIRNATY $59 4 payments
  10. NURTEC ODT Primary Care $27 1 payment
  11. Other $89 7 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 66 drugs

Part D claims

2,800

Median for Internal Medicine: 777

Drug cost

$78,027

Median for Internal Medicine: $73,373

Branded share of claims

17.7%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 22 $19,200
Mounjaro Tirzepatide Brand 14 $14,464
Aimovig Autoinjector Erenumab-Aooe Brand 12 $8,353
Atorvastatin Calcium Generic 334 $2,790
Synthroid Levothyroxine Sodium Brand 35 $2,781
Duloxetine Hcl Generic 97 $2,298
Omeprazole Generic 159 $2,282
Levothyroxine Sodium Generic 126 $1,898
Albuterol Sulfate Hfa Albuterol Sulfate Brand 52 $1,335
Venlafaxine Hcl Er Venlafaxine Hcl Brand 34 $1,216

The 10 drugs with the highest cost, of 66 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$12,510

Medicare's payments for the services billed

Medicare patients

69

Average age 74

Services billed

181

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Arthritis 45%
Diabetes 32%
Depression 17%
Cancer 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Xeomin
  • MERZ NORTH AMERICA, INC. $139
$139 — —
NURTEC ODT
  • PFIZER INC. $29
$29 — —
ZAVZPRET
  • PFIZER INC. $29
$29 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

49 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Rhode Island

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record